Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Nursing Perspectives
Video Expert Opinion
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured
Published in Renal Cell Carcinoma

Expert Opinion / Cases · May 25, 2021

Management of Rare RCC Subtypes—Chromophobe Renal Cell Carcinoma

Nazli Dizman MD

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Nazli Dizman MD

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • emine sevil bavbek

    May 26, 2021

    Metastatectomy if feasible. Anti VEGF TKI if  complete surgery not possible

  • Giuseppe Di Lucca

    May 28, 2021

    1. Surgery and/or SBRT  2. Cabozantinib

  • Laszlo Torday

    May 31, 2021

    Consider local ablative therapy first (metastasectomy or SBRT). If it is not feasible, I would do a biopsy and test the sample for PD-1 and cMET. Then, based on the result, you can choose sunitinib, cabozantinib, or pembrolizumab. And I would also review the circumstances of everolimus toxicity, focusing on dose reductions and supporting measures.

  • Dec 18, 2024

    Pending Moderator approval.
    Delete

Further Reading

Recently Updated